<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878069</url>
  </required_header>
  <id_info>
    <org_study_id>LBI-2279-004</org_study_id>
    <nct_id>NCT03878069</nct_id>
  </id_info>
  <brief_title>Registry Study of Revcovi Treatment in Patients With ADA-SCID</brief_title>
  <official_title>Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to develop a registry of patients with adenosine deaminase&#xD;
      severe combined immune deficiency (ADA-SCID) treated with Revcovi™ that contains clinical and&#xD;
      biochemical assessments for safety and dose adjustment based on adenosine deaminase (ADA)&#xD;
      activity and erythrocyte deoxyadenosine nucleotide (dAXP) levels as well as immunologic&#xD;
      monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ADA-SCID who require treatment with Revcovi as Enzyme Replacement Therapy (ERT)&#xD;
      will be enrolled during a 24-month period and each will be followed for 24 months after&#xD;
      starting Revcovi or until undergoing hematopoietic stem cell transplant (HSCT) or&#xD;
      hematopoietic stem cell gene therapy (HSC-GT), whichever occurs first. Patients undergoing&#xD;
      HSCT or HSC-GT will be followed one month after last Revcovi dose and again at six months to&#xD;
      assess adverse events (AEs) and survival. Throughout the duration of the study, patients will&#xD;
      be assessed continually for AEs.&#xD;
&#xD;
      Patients/Parents/Caregivers will self-administer weekly intramuscular (IM) dose(s) of Revcovi&#xD;
      and will be followed according to the Suggested Schedule of Assessments for trough dAXP and&#xD;
      ADA activity. Treatment dosing and monitoring will be individualized per provider and patient&#xD;
      characteristics in adherence with each study sites' standards of care.&#xD;
&#xD;
      Participants in the STP-2279-002 trial will be given the opportunity to enroll in this&#xD;
      registry study and proceed to the Treatment Month 6 Visit per the Suggested Schedule of&#xD;
      Assessments for Adagen-Transitioning Patients.&#xD;
&#xD;
      An interim analysis will be performed approximately two years after study initiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Deoxyadenosine nucleotides (dAXP) activity</measure>
    <time_frame>Month 24</time_frame>
    <description>Total trough erythrocyte dAXP activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADA activity</measure>
    <time_frame>Month 24</time_frame>
    <description>Trough plasma ADA activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune status (SSA/PI)</measure>
    <time_frame>Month 24</time_frame>
    <description>Absolute lymphocyte count and subset B, T, and NK analysis.&#xD;
Immunoglobulin (Ig) concentrations (IgG, IgA, and IgM).&#xD;
Measurement of immune response at Investigator discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status</measure>
    <time_frame>Month 24</time_frame>
    <description>Infections (clinically or microbiologically documented) Incidence and duration of hospitalizations Growth for patients &lt; 18 years old Overall survival through the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by determining adverse events (AEs), serious adverse events (SAEs)</measure>
    <time_frame>Month 24</time_frame>
    <description>Assessed by determining adverse events (AEs), serious adverse events (SAEs), clinical signs and symptoms from physical examinations, and laboratory examinations</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adenosine Deaminase Deficiency</condition>
  <condition>Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>ERT with ADA</arm_group_label>
    <description>Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>elapegademase-lvlr</intervention_name>
    <description>Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at &gt; 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.&#xD;
At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is &lt; 30 mmol/hr/L, dAXP is &gt; 0.02 mmol/L, and/or the immune reconstitution is inadequate.&#xD;
Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity &gt; 30 mmol/hr/L, dAXP &lt; 0.02 mmol/L, and/or to maintain adequate immune reconstitution.</description>
    <arm_group_label>ERT with ADA</arm_group_label>
    <other_name>Revcovi</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who receive at least one dose of study drug and have at least one safety&#xD;
        evaluation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosis of ADA-SCID who require ERT with ADA as judged by the treating&#xD;
             physicians, based on the medical history, biochemical test or genotyping.&#xD;
&#xD;
          -  Understanding and willing to comply with the Registry recommendations via signed and&#xD;
             dated written informed consent/assent.&#xD;
&#xD;
          -  ADA-SCID patient requiring Revcovi as an ERT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator, makes the patient unsuitable&#xD;
             for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chiesi Clinical Trial Info</last_name>
    <phone>+39.0521 2791</phone>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holly K Miller, MD</last_name>
      <phone>602-933-0920</phone>
      <email>hmiller2@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Holly K Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Stephens, MD</last_name>
      <phone>310-210-8771</phone>
      <email>AVStephens@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Manish Butte, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF - University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morna Dorsey, MD</last_name>
      <phone>415-476-3086</phone>
      <email>Morna.Dorsey@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morna Dorsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida Allergy Immunology Clinic</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolan Walter, MD, PhD</last_name>
      <phone>727-553-1258</phone>
      <email>jolanwalter@usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maryssa Ellison</last_name>
      <email>mellison@usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jolan Walter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Wall, MD</last_name>
      <phone>504-896-9589</phone>
      <email>lwall@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Luke Wall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital - Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey J. Bednarski, MD</last_name>
      <phone>314-286-2825</phone>
      <email>bednarski_j@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey J. Bednarski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UBMD Pediatrics Outpatient Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lehman, MD</last_name>
      <phone>716-323-0130</phone>
      <email>hkm@buffalo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Helena McClenahan</last_name>
      <email>hmcclenahan@upa.chob.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Heather Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy B Fausnight, MD</last_name>
      <phone>717-531-1846</phone>
      <email>tfausnight@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Tracy B Fausnight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hey Chong, MD</last_name>
      <phone>412-692-7785</phone>
      <email>hey.chong@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hey Chong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Elapegademase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

